SCHEMBL27612467

SCHEMBL27612467

CCOC(=O)c1cnc(Cl)nc1NC(Cc1ccccc1)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.48
▸ RAB9A P51151 4/20 0.48
▸ NPSR1 Q6W5P4 4/20 0.48
▸ ALDH1A1 P00352 8/20 0.46
▸ SMN1; SMN2 Q16637 6/20 0.46
▸ TSHR P16473 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ NFKB1 P19838 3/20 0.46
▸ NFKB2 Q00653 3/20 0.46
▸ RELA Q04206 3/20 0.46
▸ MAPT P10636 6/20 0.46
▸ LMNA P02545 4/20 0.46
▸ MAPK1 P28482 3/20 0.46
▸ SYK P43405 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ CYP1A2 P05177 2/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ ALOX15 P16050 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657038 1.00 ELANE (0.48) ELANERAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL27612449 0.94 ELANE (0.44) ELANERAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17417261 0.94 RAB9A (0.48) RAB9ANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL30431564 0.86 RAB9A (0.47) RAB9ANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL27612355 0.83 SYK (0.47) RAB9ANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL655671 0.83 SYK (0.47) RAB9ANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL27612649 0.83 RAB9A (0.54) ELANERAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL653156 0.83 RAB9A (0.54) ELANERAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL30430694 0.81 ALDH1A1 (0.64) RAB9ANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL34462345 0.81 NPSR1 (0.65) RAB9ANPSR1ALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1678321-A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC (US) 2005-10-05 — — CN disclosed
Send feedback